These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16534099)

  • 21. Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments.
    Schoenfeld DA
    Crit Care; 2005 Feb; 9(1):34-6; discussion 34-6. PubMed ID: 15693981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of database controls in pilot or futility studies in ALS.
    Czaplinski A; Haverkamp LJ; Yen AA; Simpson EP; Lai EC; Appel SH
    Neurology; 2006 Nov; 67(10):1827-32. PubMed ID: 17130417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
    Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Picking the winners in a sea of plenty.
    Scher HI; Heller G
    Clin Cancer Res; 2002 Feb; 8(2):400-4. PubMed ID: 11839655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Milestones in movement disorders clinical trials: advances and landmark studies.
    Olanow CW; Wunderle KB; Kieburtz K
    Mov Disord; 2011 May; 26(6):1003-14. PubMed ID: 21626545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
    Sakamoto J; Morita S
    Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Surrogate endpoints].
    Hill C
    Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The placebo response in Parkinson's disease. Parkinson Study Group.
    Shetty N; Friedman JH; Kieburtz K; Marshall FJ; Oakes D
    Clin Neuropharmacol; 1999; 22(4):207-12. PubMed ID: 10442249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On group sequential designs comparing two binomial proportions.
    Kepner JL
    J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early stopping designs based on progression-free survival at an early time point in the initial cohort.
    Litwin S; Wong YN; Hudes G
    Stat Med; 2007 Oct; 26(24):4400-15. PubMed ID: 17345568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.